Compare HONA & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HONA | TAK |
|---|---|---|
| Founded | N/A | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5B | 57.6B |
| IPO Year | 2025 | 2007 |
| Metric | HONA | TAK |
|---|---|---|
| Price | $154.80 | $18.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 2.0M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.16 |
| Revenue Next Year | N/A | $1.22 |
| P/E Ratio | ★ N/A | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $149.19 | $12.99 |
| 52 Week High | $266.62 | $19.10 |
| Indicator | HONA | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 50.76 |
| Support Level | $149.61 | $17.95 |
| Resistance Level | $173.29 | $18.51 |
| Average True Range (ATR) | 5.96 | 0.20 |
| MACD | 0.40 | -0.05 |
| Stochastic Oscillator | 30.41 | 37.00 |
Honeywell Aerospace Inc operates as an aerospace and defense supplier of systems and technologies that enable the production, maintenance, and safe operation of aerospace and defense platforms. Its products support original equipment manufacturer (OEM), government, defense prime contractor, and aircraft operator customers across the Commercial Air Transport, Business Aviation, and Defense and Space end markets. The company has three operating segments: Electronic Solutions (ES), Engines & Power Systems (E&PS), and Control Systems (CS ). The majority of revenue is derived from the Electronic Solutions segment, which offers Avionics, Navigation and Sensors, Electromagnetic Defensive Solutions, and Space systems. Geographically, the maximum revenue is generated from the United States.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.